touchPODCAST

By touchpodcast

Welcome to touchPODCAST where you can listen and learn from our expert faculty, hand-picked from the Touch Medical Media family of independent medical websites.

Educating physicians on a fully global... more

· Science

Download on the App Store

Download on the App Store

Get it on Google Play

FAQs about touchPODCAST:

How many episodes does touchPODCAST have?

The podcast currently has 542 episodes available.

touchPODCAST episodes:

March 18, 2025Expanding horizons for patients with Pompe disease: Using data to guide clinical practice
touchCONGRESS for touchNEUROLOGY
Listen to world-leading expert Prof. Tahseen Mozaffar as he reviews key data on current and emerging treatment options for Pompe disease presented at the 29th Annual Congress of the World Muscle Society, and 21st Annual WORLDSymposium 2025. Prof. Mozaffar is then joined by fellow experts Dr Jennifer L Cohen and Prof. Benedikt Schoser to discuss how these data may apply in clinical practice.
Overview
Data reviews with Prof. Mozaffar,
Expert panel discussions with Prof. Mozaffar, Dr Cohen and Prof. Schoser on the themes below
Clinical themes
Clinical and real-world data on long-term outcomes in Pompe disease
Outcomes and impact of treatment switching in Pompe disease
Latest clinical data on current and emerging therapies in Pompe disease
The internationally renowned Pompe disease expert faculty
Prof. Tahseen Mozaffar, Irvine, CA, USA
Dr Jennifer L Cohen, Durham, NC, USA
Prof. Benedikt Schoser, Munich, Germany
This touchPODCAST is for HCPs outside of the UK only.
This activity is funded by an independent medical education grant from Amicus Therapeutics.
This activity is jointly provided by USF Health and touchIME.
touchIME is an EBAC® accredited provider.
For further information visit our website:
...more
1h 7min
March 18, 2025Expanding horizons for patients with Pompe disease Using data to guide clinical practice
touchCONGRESS for touchRESPIRATORY
Listen to world-leading expert Prof. Tahseen Mozaffar as he reviews key data on current and emerging treatment options for Pompe disease presented at the 29th Annual Congress of the World Muscle Society, and 21st Annual WORLDSymposium 2025. Prof. Mozaffar is then joined by fellow experts Dr Jennifer L Cohen and Prof. Benedikt Schoser to discuss how these data may apply in clinical practice.
Overview
Data reviews with Prof. Mozaffar,
Expert panel discussions with Prof. Mozaffar, Dr Cohen and Prof. Schoser on the themes below
Clinical themes
Clinical and real-world data on long-term outcomes in Pompe disease
Outcomes and impact of treatment switching in Pompe disease
Latest clinical data on current and emerging therapies in Pompe disease
The internationally renowned Pompe disease expert faculty
Prof. Tahseen Mozaffar, Irvine, CA, USA
Dr Jennifer L Cohen, Durham, NC, USA
Prof. Benedikt Schoser, Munich, Germany
This touchPODCAST is for HCPs outside of the UK only.
This activity is funded by an independent medical education grant from Amicus Therapeutics.
This activity is jointly provided by USF Health and touchIME.
touchIME is an EBAC® accredited provider.
For further information visit our website:
...more
1h 7min
March 06, 2025 MDT perspectives on the importance of patient engagement in PARPi use - Video 3
touchMDT for touchONCOLOGY
Listen to experts Dr Alicia Morgans, Dr Grace Cullen, and patient advocate, Mr Tony Collier, discuss the importance and practicalities of engaging patients in their care and hear insights from the perspective of a patient advocate in relation to the use of PARP inhibitors.
The multidisciplinary team and patient advocate:
Medical oncologist – Dr Alicia Morgans
Dana-Farber Cancer Institute, Boston, Massachusetts, USA
Nurse practitioner – Dr Grace Cullen
John D. Dingell VA Medical Center, Detroit, Michigan, USA
Patient Advocate – Mr Tony Collier
Tackle Prostate Cancer, London, UK
This touchPODCAST is for HCPs outside of the UK only.
This activity is supported by an independent medical education funding request from AstraZeneca.
This activity is jointly provided by USF Health and touchIME.
touchIME is an EBAC® accredited provider.
For further information visit our website: https://touchoncologyime.org/mdt-parp-inhibitors-in-mcrpc/

...more
14min
March 06, 2025 MDT perspectives on understanding precision medicine to guide PARPi use in mCRPC - Video 2
touchMDT for touchONCOLOGY
Somatic and germline testing are key in managing metastatic castration-resistant prostate cancer (mCRPC). Listen as Prof. Albrecht Stenzinger shares his perspectives as a pathologist with Dr Alicia Morgan and Dr Grace Cullen.
The multidisciplinary team:
Medical oncologist – Dr Alicia Morgans
Dana-Farber Cancer Institute, Boston, Massachusetts, USA
Nurse practitioner – Dr Grace Cullen
John D. Dingell VA Medical Center, Detroit, Michigan, USA
Pathologist – Prof. Albrecht Stenzinger
University of Heidelberg, Heidelberg, Germany
This touchPODCAST is for HCPs outside of the UK only.
This activity is supported by an independent medical education funding request from AstraZeneca.
This activity is jointly provided by USF Health and touchIME.
touchIME is an EBAC® accredited provider.
For further information visit our website: https://touchoncologyime.org/mdt-parp-inhibitors-in-mcrpc/
...more
14min
March 06, 2025 MDT perspectives on unlocking the data on PARPi to support shared decision-making in mCRPC - Video 1
touchMDT for touchONCOLOGY
MDT perspectives on unlocking the data on PARPi to support shared decision-making in mCRPC
Experts Dr Alicia Morgans and Dr Grace Cullen share insights into using evidence to guide practice and shared decision-making with patients with metastatic castration-resistant prostate cancer (mCRPC).
The multidisciplinary team:
Medical oncologist – Dr Alicia Morgans
Dana-Farber Cancer Institute, Boston, Massachusetts, USA
Nurse practitioner – Dr Grace Cullen
John D. Dingell VA Medical Center, Detroit, Michigan, USA
This touchPODCAST is for HCPs outside of the UK only.
This activity is supported by an independent medical education funding request from AstraZeneca.
This activity is jointly provided by USF Health and touchIME.
touchIME is an EBAC® accredited provider.
For further information visit our website: https://touchoncologyime.org/mdt-parp-inhibitors-in-mcrpc/
...more
14min
February 27, 2025The next frontier in managing obesity and T2D: The role of novel combinations for touchCARDIO
touchEXPERT OPINIONS for touchCARDIO

Listen to three experts discuss the rationale behind glucagon-like peptide-1 (GLP-1)-based combination therapies and review the latest clinical evidence for these novel combinations. The expert faculty will provide their insights on what these combination treatments may mean for the future management of obesity with or without type 2 diabetes (T2D).

The experts
Dr Sue Pedersen, University of Calgary, Calgary, Canada
Prof. Carel le Roux, University College Dublin, Dublin, Ireland
Dr Donna Ryan, Pennington Biomedical Research Center, Baton Rouge, LA, USA
This touchPODCAST is for healthcare professionals outside of the USA and UK.

This activity is funded by an independent medical education grant from Novo Nordisk A/S.

This activity is jointly provided by USF Health and touchIME.
touchIME is an EBAC® accredited provider.

For further information visit our website:
www.touchCARDIO.com
...more
33min
February 27, 2025The next frontier in managing obesity and T2D: The role of novel combinations for touchENDOCRINOLOGY
touchEXPERT OPINIONS for touchENDOCRINOLOGY

Listen to three experts discuss the rationale behind glucagon-like peptide-1 (GLP-1)-based combination therapies and review the latest clinical evidence for these novel combinations. The expert faculty will provide their insights on what these combination treatments may mean for the future management of obesity with or without type 2 diabetes (T2D).
The experts
Dr Sue Pedersen, University of Calgary, Calgary, Canada
Prof. Carel le Roux, University College Dublin, Dublin, Ireland
Dr Donna Ryan, Pennington Biomedical Research Center, Baton Rouge, LA, USA
This touchPODCAST is for healthcare professionals outside of the USA and UK.

This activity is funded by an independent medical education grant from Novo Nordisk A/S.

This activity is jointly provided by USF Health and touchIME.
touchIME is an EBAC® accredited provider.
For further information visit our website:
www.touchENDOCRINOLOGY.com
...more
33min
February 21, 2025From clinical trials to clinical practice: Applying CDK4/6 inhibitors in HR+/HER2– early breast cancer
touchEXPERT OPINIONS for touchONCOLOGY
Listen to three experts in breast cancer as they provide insights into the current guideline recommendations for the use of targeted therapy in patients with HR+/HER2– early breast cancer, evaluate the latest data for CDK4/6 inhibitors in this patient population and consider how to maximize the potential of these agents through risk stratification and safety considerations.

The experts
Prof. Carlos Barrios: Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil
Prof. Dr. med. Peter Fasching: University Hospital Erlangen and Comprehensive Cancer Center, Erlangen-EMN, Germany
Dr Sonia Pernas: Catalan Institute of Oncology-Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain

This touchPODCAST is for healthcare professionals outside of the UK and the USA.
This activity is funded by an independent medical education grant from Novartis.
This activity is provided by touchIME.

For further information visit our website:
www.touchONCOLOGY.com
...more
37min
February 20, 2025Cervical cancer prevention and beyond: Optimizing HPV vaccine uptake in all eligible individuals
touchIN CONVERSATION for touchONCOLOGY

Listen to a paediatrician specializing in adolescent medicine and a general practitioner specializing in sexual health as they address healthcare professionals' questions on HPV vaccination. They provide insights into the burden of HPV-related oncological and non-oncological diseases, appropriate vaccination schedules for specific patient groups, and strategies to improve vaccine uptake across various healthcare settings.

The experts
Dr Barbara Moscicki, UCLA Health and University of California, Los Angeles, CA, USA
Dr Marc Steben, HPV Global Action and Université de Montréal, Canada
This touchPODCAST is for HCPs outside of the UK only.
This activity is funded by an independent medical education grant from Merck Sharp & Dohme LLC.
This activity is jointly provided by USF Health and touchIME.
touchIME is an EBAC® accredited provider.
For further information visit our website:
https://touchoncologyime.org/in-conversation-improving-hpv-vaccine-uptake/
...more
37min
February 20, 2025Cervical cancer prevention and beyond: Optimizing HPV vaccine uptake in all eligible individuals
touchIN CONVERSATION for touchINFECTIOUS DISEASES

Listen to a paediatrician specializing in adolescent medicine and a general practitioner specializing in sexual health as they address healthcare professionals' questions on HPV vaccination. They provide insights into the burden of HPV-related oncological and non-oncological diseases, appropriate vaccination schedules for specific patient groups, and strategies to improve vaccine uptake across various healthcare settings.

The experts
Dr Barbara Moscicki, UCLA Health and University of California, Los Angeles, CA, USA
Dr Marc Steben, HPV Global Action and Université de Montréal, Canada
This touchPODCAST is for HCPs outside of the UK only.
This activity is funded by an independent medical education grant from Merck Sharp & Dohme LLC.
This activity is jointly provided by USF Health and touchIME.
touchIME is an EBAC® accredited provider.
For further information visit our website:
https://touchinfectiousdiseasesime.org/in-conversation-improving-hpv-vaccine-uptake/
...more
37min

FAQs about touchPODCAST:

How many episodes does touchPODCAST have?

The podcast currently has 542 episodes available.